 |
Buy Zanaflex online |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
 |
ZanaflexBelow is a quick price comparison for Zanaflex. All prices include shipping and consultation fees. There are no more hidden costs for you.  You can save a lot of money by buying Zanaflex in bulk. This requires a larger up-front investment but the saving is enormous.
ZANAFLEX (tizanidine hydrochloride) works centrally in the brain by effecting adrenergic nerve receptors. Zanaflex is a white to off-white, fine crystalline powder, odorless or with a faint characteristic odor.
Zanaflex is a muscle relaxer. Zanaflex is a prescription medication that is now available for your purchase online. You should never take more than one Zanaflex at a time. Driving can be dangerous when using Zanaflex because it is a muscle relaxer and you could become tired or groggy. Zanaflex is most often used to treat muscle pain, muscle cramps and muscle spasms. Those who have muscle disorders or muscle problems are the number one users of Zanaflex around the world. If you have had an injury to you arm, leg, back or neck and you experience muscle spasms then Zanaflex can help your muscles relax. Mechanism of Action Zanaflex is a stimulant at the adrenergic receptor sites of the brain. Zanaflex presumably reduces spasticity by increasing inhibition of motor neurons. In animal models, Zanaflex has no direct effect on skeletal muscle. Pharmacokinetics Following oral administration, Zanaflex is essentially completely absorbed and has a half-life of approximately 2.5 hours. Following administration of Zanaflex, peak plasma concentrations occurred at 1.5 hours after dosing. Food increases C max by approximately one-third and shortens time to peak concentration by approximately 40 minutes, but the extent of Zanaflex absorption is not affected. Zanaflex has linear pharmacokinetics over a dose of 1 to 20 mg. The absolute oral bioavailability of Zanaflex is approximately 40% (CV = 24%), due to extensive first-pass metabolism in the liver; approximately 95% of an administered dose is metabolized. Zanaflex metabolites are not known to be active; their half-lives range from 20 to 40 hours. Zanaflex is widely distributed throughout the body; mean steady state volume of distribution is 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers. Special Populations Age Effects: No specific pharmacokinetic study was conducted to investigate age effects on Zanaflex. Cross study comparison of pharmacokinetic data following single dose administration of 6 mg Zanaflex showed that younger subjects cleared the drug four times faster than the elderly subjects. Zanaflex has not been evaluated in children. Hepatic Impairment: Pharmacokinetic differences in Zanaflex due to hepatic impairment have not been studied. Kidney Impairment: Zanaflex clearance is reduced by more than 50% in elderly patients with kidney insufficiency compared to healthy elderly subjects; this would be expected to lead to a longer duration of clinical effect. Zanaflex should be used with caution in renally impaired patients. Gender Effects: No specific pharmacokinetic study was conducted to investigate gender effects on Zanaflex. Retrospective analysis of pharmacokinetic data, however, following single and multiple dose administration of 4 mg Zanaflex showed that gender had no effect on the pharmacokinetics of Zanaflex. Race Effects: Pharmacokinetic differences due to race with Zanaflex have not been studied. Drug Interactions-Oral Contraceptives: No specific pharmacokinetic study was conducted to investigate interaction between oral contraceptives and Zanaflex. Retrospective analysis of population pharmacokinetic data following single and multiple dose administration of 4 mg Zanaflex, however, showed that women concurrently taking oral contraceptives had 50% lower clearance of Zanaflex compared to women not on oral contraceptives. CLINICAL STUDIES Zanaflex 's capacity to reduce increased muscle tone associated with spasticity was demonstrated in two adequate and well controlled studies in patients with multiple sclerosis or spinal cord injury. In one study, patients with multiple sclerosis were randomized to receive single oral doses of Zanaflex or placebo. Patients and assessors were blind to treatment assignment and efforts were made to reduce the likelihood that assessors would become aware indirectly of treatment assignment (e.g., they did not provide direct care to patients and were prohibited from asking questions about side effects). In all, 140 patients received either placebo, 8 mg or 16 mg of Zanaflex. Response was assessed by physical examination; muscle tone was rated on a 5 point scale (Ashworth score), with a score of 0 used to describe normal muscle tone. A score of 1 indicated a slight spastic catch while a score of 2 indicated more marked muscle resistance. A score of 3 was used to describe considerable increase in tone, making passive movement difficult. A muscle immobilized by spasticity was given a score of 4. Spasm counts were also collected. Assessments were made at 1, 2, 3 and 6 hours after treatment. A statistically significant reduction of the Ashworth score for Zanaflex compared to placebo was detected at 1, 2 and 3 hours after treatment. The greatest reduction in muscle tone was 1 to 2 hours after Zanaflex treatment. By 6 hours after treatment, muscle tone in the 8 and 16 mg Zanaflex groups was indistinguishable from muscle tone in placebo treated patients. Within a given patient, improvement in muscle tone was correlated with Zanaflex plasma concentration. Zanaflex plasma concentrations were variable from patient to patient at a given dose. Although 16 mg of Zanaflex produced a larger effect, adverse Zanaflex events including hypotension were more common and more severe than in the 8 mg group. There were no differences in the number of spasms occurring in each group. In a multiple dose study, 118 patients with spasticity secondary to spinal cord injury were randomized to either placebo or Zanaflex. Steps similar to those taken in the first study were employed to ensure the integrity of blinding. Patients were titrated over 3 weeks up to a maximum tolerated dose or 36 mg daily given in three unequal doses (e.g., 10 mg given in the morning and afternoon and 16 mg given at night). Patients were then maintained on their maximally tolerated Zanaflex dose for 4 additional weeks (i.e., maintenance phase). Throughout the Zanaflex maintenance phase, muscle tone was assessed on the Ashworth scale within a period of 2.5 hours following either the morning or afternoon dose. The number of daytime spasms was recorded daily by patients. At endpoint (the protocol-specified time of outcome assessment), there was a statistically significant reduction in muscle tone and frequency of spasms in the Zanaflex treated group compared to placebo. The reduction in muscle tone was not associated with a reduction in muscle strength (a desirable outcome) but also did not lead to any consistent advantage of Zanaflex treated patients on measures of activities of daily living. INDICATIONS AND USAGE Zanaflex is a short-acting drug for the management of muscle spasticity. Because of the short duration of effect, treatment with Zanaflex should be reserved for those daily activities and times when relief of spasticity is most important. CONTRAINDICATIONS Zanaflex is contraindicated in patients with known hypersensitivity to Zanaflex or its ingredients. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
